PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer

PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.